1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
LungLife AI, Inc.

LungLife AI, Inc.

LLA.L
LungLife AI, Inc.GB flagLondon Stock Exchange
5.00
GBp
- -
- -
1.30MMarket Cap
LungLife AI, Inc.
LLA.L
(London Stock Exchange)

Recent

price

5.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
FRC
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
1
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
-229.73
-2,499.93
-1,815.3
-2,740.51
-29,683.33
-12,560.87
Operating Margin (%)
- -
- -
- -
- -
- -
- -
Depreciation Expense
-3
-4
-5
-7
-8
-5
Net Income, GAAP
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-330.92
-3,060.76
-2,358.43
-3,817.44
-31,691.67
-11,767.39
Profit Margin (%)
-1
-7
-12
14
7
2
Working Capital
3
- -
- -
1
- -
- -
LT Debt
-3
-7
-11
20
13
8
Total Equity
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-33.39%
-39.78%
Free Cash Flow
- -
43.76%
-14.05%
Net Income, GAAP
- -
14.31%
-28.83%
Sales/Revenue/Turnover
- -
-7.35%
91.67%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Leveljump Healthcare Corp. (JMPHF)
Izotropic Corporation (IZOZF)
BML, Inc. (4694.T)
BIONET Corp. (1784.TWO)
Twist Bioscience Corporation (TWST)
Genetic Signatures Limited (GSS.AX)
Business
LungLife AI, Inc. (AIM: LLAI) develops AI-enhanced clinical diagnostic solutions for early lung cancer detection through non-invasive liquid biopsy technology. The company offers LungLB, a blood-based test that stratifies cancerous and benign lung nodules identified via CT scans and monitors recurrence post-surgery; companion diagnostics for later-stage treatment selection and clinical trial patient stratification; and related testing, cancer monitoring, and consultative services performed in its CLIA-certified laboratory in California. Incorporated in 2009 as Cynvenio Biosystems, Inc. and renamed LungLife AI in 2019, the company is headquartered in Dover, Delaware, with operations primarily in the United States, including facilities in California. LungLife AI targets clinicians, healthcare providers, and medical research institutes managing indeterminate lung nodules, estimated at over 1.5 million annually in the US. In April 2025, the company entered a conditional exclusive license and distribution agreement with Circulogene Theranostics, Inc. for commercial rollout of the LungLB test across the US; it also proposed cancellation of AIM trading admission, held a special stockholder meeting in May 2025 approving related resolutions, and issued multiple TR-1 major holdings notifications through May 2025.